Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP102 Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33)

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
OP102
  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Host
M
Description
Overview

This product has been discontinued.





Recognizes the ~30 kDa von Hippel-Lindau (VHL) protein in prostate, lung, colon, breast, bladder or carcinoma tissue.
Catalogue NumberOP102
Brand Family Calbiochem®
References
ReferencesCorliss, C.L., et al. 1997.Human Pathology 28, 459.
Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
Chen, F., et al. 1995. Cancer Res. 55, 4804.
Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
Duan, D.R., et al. 1995. Science 269, 1402.
Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
Kishida, T., et al. 1995. Cancer Res. 55, 4544.
Kley, N., et al. 1995. Glia 15, 297.
Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
Product Information
FormLiquid
FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
Positive controlProstate, kidney, lung, colon, breast, bladder, or thyroid carcinoma tissue
Preservative≤0.1% sodium azide
Applications
Application ReferencesOriginal Clone Kibel, A., et al. 1995. Science 269, 1444.
Key Applications Immunoblotting (Western Blotting)
Paraffin Sections
Application NotesImmunoblotting (1-2 µg/ml)
Paraffin Sections (2-4 µg/ml; heat pre-treatment required, see comments)
Application CommentsPrior to staining formalin-fixed, paraffin-embedded tissue sections, boil the tissue in 1 mM EDTA, pH 8.0, for 10-20 min, followed by cooling at room temperature for 20 min. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogena recombinant fusion protein consisting of amino acids 1-213 of human VHL
ImmunogenHuman
CloneIg33
HostMouse
IsotypeIgG₁
Concentration Label Please refer to vial label for lot-specific concentration
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Standard Handling
Storage +2°C to +8°C
Avoid freeze/thaw Avoid freeze/thaw
Do not freeze Ok to freeze
Special InstructionsFollowing initial use, aliquot and freeze (-20°C) for long-term storage.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
OP102 0

Documentation

Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33) SDS

Title

Safety Data Sheet (SDS) 

Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33) Certificates of Analysis

TitleLot Number
OP102

References

Reference overview
Corliss, C.L., et al. 1997.Human Pathology 28, 459.
Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
Chen, F., et al. 1995. Cancer Res. 55, 4804.
Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
Duan, D.R., et al. 1995. Science 269, 1402.
Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
Kishida, T., et al. 1995. Cancer Res. 55, 4544.
Kley, N., et al. 1995. Glia 15, 297.
Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision09-July-2007 RFH
ApplicationImmunoblotting (1-2 µg/ml)
Paraffin Sections (2-4 µg/ml; heat pre-treatment required, see comments)
DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes the ~30 kDa von Hippel-Lindau protein (VHL).
BackgroundVon Hippel-Lindau disease is a rare tumor syndrome that is characterized by cerebellar and spinal hemangioblastomas and retinal angiomas. Molecular studies suggest that VHL is a tumor suppressor gene, which is inactivated or mutated in von Hippel-Lindau disease as well as in clear-cell renal carcinomas (RCC). The gene is affected in both hereditary and in sporadic tumors. In clear-cell renal carcinomas there is loss of function of both copies of the gene suggesting a role in proliferation control. This hypothesis is borne out by the observation that transfection of the wild type protein will inhibit cell growth. Initially identified in 1993, the VHL protein has a bipartite localization, it is found localized to the cytoplasm in densely cultured cells but in the nucleus in sparse cell cultures. The primary functional target of VHL protein is the transcription elongation complex in particular, the elongin proteins B and C which bind in vitro and in vivo to a short, colinear region of the VHL protein that is frequently mutated in human tumors. In addition to the elongins, VHL has been shown to bind to other proteins including the HIV tat-binding protein, filamin and VBP-1, and two other VHL binding proteins, p14 (p16) and p10 (p9). More recently, VHL has been shown to control VEGF expression in several different tumors, affecting primarily the splice variants VEGF121 and VEGF165.
HostMouse
Immunogen speciesHuman
Immunogena recombinant fusion protein consisting of amino acids 1-213 of human VHL
CloneIg33
IsotypeIgG₁
Specieshuman
Positive controlProstate, kidney, lung, colon, breast, bladder, or thyroid carcinoma tissue
FormLiquid
FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
Concentration Label Please refer to vial label for lot-specific concentration
Preservative≤0.1% sodium azide
CommentsPrior to staining formalin-fixed, paraffin-embedded tissue sections, boil the tissue in 1 mM EDTA, pH 8.0, for 10-20 min, followed by cooling at room temperature for 20 min. Antibody should be titrated for optimal results in individual systems.
Storage Avoid freeze/thaw
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial use, aliquot and freeze (-20°C) for long-term storage.
Toxicity Standard Handling
ReferencesCorliss, C.L., et al. 1997.Human Pathology 28, 459.
Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
Chen, F., et al. 1995. Cancer Res. 55, 4804.
Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
Duan, D.R., et al. 1995. Science 269, 1402.
Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
Kishida, T., et al. 1995. Cancer Res. 55, 4544.
Kley, N., et al. 1995. Glia 15, 297.
Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
Application referencesOriginal Clone Kibel, A., et al. 1995. Science 269, 1444.